bioAffinity Technologies, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
bioAffinity Technologies agreed to sell up to $4,000,000 of unregistered securities (common stock, pre-funded warrants, and Series A/B warrants) to accredited investors through WallachBeth Capital, LLC as exclusive placement agent under Reg D exemption. Placement agent receives 7.5% cash fee ($300K max), up to $70K expense reimbursement, and 3% warrant coverage (253,861 shares at $0.4727 exercise price). Company required to file Form S-3 within 45 days and restricted from variable-rate transactions for 6 months.
Why this rating
18% of market cap is material in absolute terms, but standard PIPE offering with typical terms, common for micro-cap biotech. Routine capital raise absent concerning dilution metrics or going-concern language.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.